Otsuka Encounters Split Responses For Drug For Rare Kidney Disease
This article was originally published in PharmAsia News
Otsuka Pharmaceutical won one and lost one half a world apart for its Samsca (tolvaptan) for treating a rare type of kidney disease, rejected in the U.S., accepted at home in Japan.
You may also be interested in...
A final Medicare agency rule requiring insurers to reveal coverage prices for device-related procedures and tests will let consumers shop health services.
Perrigo says on 4 November, Irish High Court will publish decision from a trial on the firm’s challenge to Irish Office of the Revenue Commissioners’ order to pay additional taxes from its acquisition of Elan. Perrigo moved its Q3 earnings briefing scheduled for 8 a.m. EDT the same day to 4:30 p.m.
Part of a broad rule that also aims to fix a coverage gap for COVID-19 vaccines, the payment policy differs from NTAP in that manufacturers of COVID therapies won’t have to formally apply and the add-on payments will not take the cost of the COVID products into account.